Contents

Part I  What Parp is and What it Does

1  History of the Discovery of Poly (ADP-ribose) ........................................... 3
Takashi Sugimura and Sydney Shall

2  Discovery of the PARP Superfamily and Focus on the Lesser Exhibited But Not Lesser Talented Members .............................................. 15
Eléa Héberlé, Jean-Christophe Amé, Giuditta Illuzzi, Françoise Dantzer and Valérie Schreiber

3  The Role of PARPs in DNA Strand Break Repair ....................................... 47
Stuart L. Rulten, Françoise Dantzer and Keith W. Caldecott

4  TIPS: Tankyrase Interacting Proteins ............................................................ 79
Susan Smith

5  PARP and Carcinogenesis ........................................................................... 99
Junhui Wang, Akira Sato, Hiroaki Fujimori, Yoshio Miki and Mitsuko Masutani

6  Multitasking Roles for Poly(ADP-ribosyl)ation in Aging and Longevity ................................................................. 125
Aswin Mangerich and Alexander Bürkle

Part II  NAD Catalysis and the Identification of Inhibitors

7  Overview of PARP Inhibitor Design and Optimization ........................... 183
Dana Ferraris

8  Structure Based Design of PARP Inhibitors .............................................. 205
Stacie S. Canan
Part III  Chemo- and Radiosensitisation in Vitro and in Vivo

9 Preclinical Chemosensitization by PARP Inhibitors ................................. 225
   David R. Shalinsky, Cherrie K. Donawho, Gerrit Los and Joann P. Palma

10 Classification of PARP Inhibitors Based on PARP Trapping and Catalytic Inhibition, and Rationale for Combinations with Topoisomerase I Inhibitors and Alkylating Agents ..................... 261
   Junko Murai and Yves Pommier

11 Radiosensitisation by Poly(ADP-ribose) Polymerase Inhibition .......... 275
   Charles Fouillade, Alexis Fouquin, Mohammed-Tayyib Boudra, Vincent Favaudon, Vincent Pennaneach and Janet Hall

12 The Vasoactivity of PARP Inhibitors .............................................................. 299
   Cian M. McCrudden and Kaye J. Williams

Part IV  Synthetic Lethality

13 Synthetic Lethality with Homologous Recombination Repair Defects .......................................................... 315
   Helen E. Bryant and Sydney Shall

14 Targeting Tumour Hypoxia with PARP Inhibitors: Contextual Synthetic Lethality .............................................................. 345
   Katarzyna B. Leszczynska, Nadya Temper, Robert G. Bristow and Ester M. Hammond

15 Other Determinants of Sensitivity ................................................................. 363
   Naoyuki Okita and Atsushi Shibata

16 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway ................................................................. 381
   Jennifer A. Stanley and Eddy S. Yang

17 Disruption of DNA Repair by Cell Cycle and Transcriptional CDK Inhibition ................................................................. 413
   Liam Cornell, Neil Johnson and Geoffrey I. Shapiro

18 Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations ................................................................. 431
   Kiranjit K. Dhillon and Toshiyasu Taniguchi
19 PARP Inhibitor Resistance—What Is Beyond BRCA1 or BRCA2 Restoration? ........................................................................ 453
   Guotai Xu, Jos Jonkers and Sven Rottenberg

Part V Clinical Status

20 Introduction to PARPi Clinical Trials and Future Directions .......... 475
   Ruth Plummer and Yvette Drew

21 Clinical Trials Investigating PARP Inhibitors as Single Agents ........ 487
   Sheena Irshad and Andrew Tutt

22 Clinical Trials of PARP Inhibitors with Chemotherapy ................. 511
   Ashley K. Clift, Nicholas Coupe and Mark R. Middleton

23 Combination of PARP Inhibitors with Clinical Radiotherapy .......... 533
   Ross Carruthers and Anthony J. Chalmers

24 Biomarkers for PARP Inhibitors .................................................. 553
   Charles Dearman, Ricky A. Sharma and Nicola J. Curtin

Glossary .......................................................................................... 581

Index ............................................................................................. 589